Asymmetric Dimethylarginine is Associated with Parameters of Glucose Metabolism in Caucasian but not in African Women from South Africa

Abstract

Aim: Ethnic differences in obesity and obesity related disorders prompted us to search for possible contributors. The impact of the novel cardiovascular risk factor asymmetric dimethylarginine (ADMA) has been never determined in the African population. The present observational study aimed to compare ADMA levels between healthy African (102) and Caucasian women (115) from South Africa, and its impact on glucose metabolism.

Methods: All participants underwent an oral glucose tolerance test with measurements of glucose, insulin, C-peptide, proinsulin and free fatty acids before and after 30, 60, 90, 120 minutes. Fasting serum ADMA was measured by ELISA assay and obesity was determined by anthropometry.

Results: Serum ADMA did not differ between the ethnic groups. After stratification according to ADMA quartiles Caucasian women in the upper quartile had significantly higher body mass index and waist circumference as well as elevated insulin resistance, insulin, C-peptide and proinsulin levels with no differences in serum glucose compared to women in the lowest quartile. There was a significant stronger postchallenge insulin response in Caucasian women of the upper quartile. No differences were found in African women.

Conclusions: Despite similar ADMA levels in both ethnic groups ADMA was positively correlated with parameters of glucose metabolism in the Caucasian but not in the African women from South Africa.

asymmetric dimethylarginine - ethnicity - insulin resistance - obesity - women

References

• 1 Abbasi F, Asagmi T, Cooke JP, Lamendola C, MacLaughlin T, Reaven GM. et al . Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus.  Am J Cardiol. 2001;  88 1201-1203
• 2 Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease.  Circulation. 1997;  95 2068-2074
• 3 Boger RH, Bode-Boger SM, Kienke S, Stan AC, Nafe R, Frolich JC. Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits.  Atherosclerosis. 1998a;  136 67-77
• 4 Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O. et al . Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.  Circulation. 1998b;  98 1842-1847
• 5 Boger RH, Bode-Boger SM, Tsao PS, Lin PS, Chan JR, Cooke JP. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes.  J Am Coll Cardiol. 2000;  36 2287-2295
• 6 Boger RH. Association of asymmetric dimethylarginine and endothelial dysfunction.  Clin Chem Lab Med. 2003;  41 1467-1472
• 7 Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath Jr CW. Body-mass index and mortality in a prospective cohort of U.S. adults.  N Engl J Med. 1999;  341 1097-1105
• 8 Cossrow N, Falkner B. Race/ethnic issues in obesity and obesity-related comorbidities.  J Clin Endocrinol Metab. 2004;  89 2590-2594
• 9 Grasemann H, Drazen JM, Deykin A, Israel E, Sanctis GT De, Pillari A. et al . Simple tandem repeat polymorphisms in the neuronal nitric oxide synthase gene in different ethnic populations.  Hum Hered. 1999;  49 139-141
• 10 Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA. et al . Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary.  Cardiol Rev. 2005;  13 322-327
• 11 Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus.  Circ J. 2002;  66 811-815
• 12 Lovejoy JC, Bretonne JA de la, Klemperer M, Tulley R. Abdominal fat distribution and metabolic risk factors: effects of race.  Metabolism. 1996;  45 1119-1124
• 13 Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M, Adegoke OA. et al . Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover.  Diabetologia. 2006;  49 351-359
• 14 MacLaughlin T, Stuhlinger M, Lamendola C, Abbasi F, Bialek J, Reaven GM. et al . Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss.  J Clin Endocrinol Metab. 2006;  91 1896-1900
• 15 Norton K, Olds T. Anthropometrica. A textbook of body measurement for sports and health courses. University of New South Wales Press, Sydney 1996
• 16 World Health Organisation .Obesity. Preventing and Managing the Global Epidemic. Report of a WHO Consultation on Obesity, Geneva 1997
• 17 Paiva H, Lehtimaki T, Laakso J, Ruokonen I, Rantalaiho V, Wirta O. et al . Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy.  Metabolism. 2003;  52 303-307
• 18 Perry AC, Applegate EB, Jackson ML, Deprima S, Goldberg RB, Ross R. et al . Racial differences in visceral adipose tissue but not anthropometric markers of health-related variables.  J Appl Physiol. 2000;  89 636-643
• 19 Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH. et al . Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension.  J Am Coll Cardiol. 2005;  46 518-523
• 20 Puoane T, Steyn K, Bradshaw D, Laubscher R, Fourie J, Lambert V. et al . Obesity in South Africa: the South African demographic and health survey.  Obes Res. 2002;  10 1038-1048
• 21 Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP. et al . Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay.  Clin Chem Lab Med. 2004;  42 1377-1383
• 22 Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Boger RH. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects.  Eur J Clin Invest. 2005;  35 622-626
• 23 Schulze F, Schwedhelm E, Maas R, Boger RH. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum.  J Chromatogr B Analyt Technol Biomed Life Sci. 2006;  831 333
• 24 Schutte AE, Kruger HS, Wissing MP, Underhay C, Vorster HH. The emergence of the metabolic syndrome in urban obese African women: The POWIRS-study.  S Afr J Sci. 2005;  101 61-67
• 25 Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, MacLaughlin TL, Cooke JP. et al . Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.  Jama. 2002;  287 1420-1426
• 26 Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S. et al . Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress.  Arterioscler Thromb Vasc Biol. 2004;  24 1682-1688
• 27 Sydow K, Mondon CE, Cooke JP. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.  Vasc Med. 2005;  10 ((Suppl 1)) S35-43
• 28 Teerlink T, Neele SJ, Jong S de, Netelenbos JC, Stehouwer CD. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women.  Clin Sci (Lond). 2003;  105 67-71
• 29 Wang H, Craig RL, Schay J, Chu W, Das SK, Zhang Z. et al . Alpha-endosulfine, a positional and functional candidate gene for type 2 diabetes: molecular screening, association studies, and role in reduced insulin secretion.  Mol Genet Metab. 2004;  81 9-15
• 30 Yasuda S, Miyazaki S, Kanda M, Goto Y, Suzuki M, Harano Y. et al . Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase.  Eur Heart J. 2006;  27 1159-1165

Correspondence